Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7778609 | 0.87 | ALDH1A1 (0.66) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL831162 | 0.84 | PTGS2 (0.65) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL12526290 | 0.84 | MAPT (0.63) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL990973 | 0.82 | MAPT (0.57) | MAPTALDH1A1KMT2AMEN1GAA | |
| SCHEMBL7154441 | 0.81 | MAPT (0.56) | MAPTALDH1A1KMT2AMEN1GAA | |
| SCHEMBL18530432 | 0.81 | MAPT (0.56) | MAPTALDH1A1KMT2AMEN1GAA | |
| SCHEMBL20234288 | 0.81 | L3MBTL1 (0.51) | MAPTKMT2AMEN1 | |
| SCHEMBL8456712 | 0.80 | ALDH1A1 (0.62) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL13264901 | 0.80 | ALDH1A1 (0.62) | MAPTALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL20234291 | 0.80 | L3MBTL1 (0.50) | MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011140009-A1 | METHODS OF USING SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| EP-2373694-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | BioMarin Pharmaceutical Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20110015119-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| WO-2010065174-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015119-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | SI, FUT6, B3GAT3 | MAPT 4691/4885ALDH1A1 3289/4885POLB 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.